Key molecular targets in this process, including ODC1, AMD1, DHPS and c-Myc could serve as effective drug targets addressing specific vulnerabilities in BRAFi resistant melanoma, warranting development of novel breakthrough therapies against therapy resistant melanoma. This evidence concerns the gene MYC and melanoma.